ME02016B - Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola - Google Patents

Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola

Info

Publication number
ME02016B
ME02016B MEP-2015-9A MEP915A ME02016B ME 02016 B ME02016 B ME 02016B ME P915 A MEP915 A ME P915A ME 02016 B ME02016 B ME 02016B
Authority
ME
Montenegro
Prior art keywords
dioxabicyclo
chloro
hydroxymethyl
phenyl
compound
Prior art date
Application number
MEP-2015-9A
Other languages
English (en)
Inventor
Vincent Mascitti
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ME02016B publication Critical patent/ME02016B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (15)

1. Spoj Formule (A) ili Formule (B)naznačen time štoR je -OH ili, kada je R1 -O-C(O)-(C1-C4)alkil ili -O-C(O)-aril, R je isti kao R1 ili -OH;R1 je -OH, F, Cl, -O-C(O)-(C1-C4)alkil, -O-C(O)-aril, -O-C(O)-O-(C1-C4)alkil ili -O-C(O)-O-aril; iR2 je -OH, -O-(C1-C4)alkil ili -O-CH2-CH2-O-R2a; uz uvjet da kada je R -OH, a R1 je -OH, R2 je -OH ili -O-CH2-CH2-O-R2a;R2a je H, -C(O)-(C1-C4)alkil, -C(O)-aril, -C(O)-O-(C1-C4)alkil ili -C(O)-O-aril;i njihove farmaceutski prihvatljive soli.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je navedeni spoj spoj Formule (A).
3. Spoj u skladu s patentnim zahtjevima 1 ili 2, naznačen time što je R1 -OH.
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što je R2 -OH.
5. Spoj u skladu s patentnim zahtjevom 3, naznačen time što je R2 -O-CH2CH2OH.
6. Spoj, naznačen time što ga se bira iz skupine koju čine: (1R,2S,3S,4R,5S)-3,4-diacetoksi-1-acetoksimetil-5-[4-klor-3-(4-etoksibenzil)fenil]-6,8-dioksabiciklo[3.2.1]okt-2-ilni ester octene kiseline; (1R,2S,3S,4R,5S)-5-[4-klor-3-(4-etoksibenzil)fenil]-2,3,4-trihidroksi-6,8-dioksabiciklo[3.2.1]okt-1-ilmetilni ester octene kiseline; (1R,2S,3S,4R,5S)-5-[4-klor-3-(4-etoksibenzil)fenil]-2,3,4-trihidroksi-6,8-dioksabiciklo[3.2.1]okt-1-ilmetilni ester etilni ester ugljične kiseline; (1S,2S,3S,4R,5S)-5-[4-klor-3-(4-[D5]etoksibenzil)fenil]-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol; 2-{4-[2-klor-5-((1S,2S,3S,4R,5S)-2,3,4-trihidroksi-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]okt-5-il)benzil]fenoksi}etilni ester octene kiseline; (1S,2S,3S,4R,5S)-5-{4-klor-3-[4-(2-hidroksietoksi)benzil]fenil}-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol; i (1S,2S,3S,4R,5S)-5-[4-klor-3-(4-etoksibenzil)fenil]-1-fluormetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol; ili njihove farmaceutski prihvatljive soli.
7. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je navedeni spoj (1S,2S,3S,4R,5S)-5-[4-klor-3-(4-hidroksibenzil)fenil]-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol.
8. Spoj, naznačen time što ga se bira iz skupine koju čine: (1S,2S,3S,4R,5S)-5-{4-klor-3-[(4-etoksifenil)hidroksimetil]fenil}-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol; (1S,2S,3S,4R,5S)-5-{4-klor-3-[(R)-(4-etoksifenil)hidroksimetil]fenil}-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol; i (1S,2S,3S,4R,5S)-5-{4-klor-3-[(S)-(4-etoksifenil)hidroksimetil]fenil}-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol.
9. Farmaceutski pripravak, naznačen time što sadrži: (i) spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, ili njegovu farmaceutski prihvatljivu sol; i (ii) farmaceutski prihvatljivu pomoćni tvar, razrjeđivač, ili podlogu.
10. Pripravak u skladu s patentnim zahtjevom 9, naznačen time što je navedeni spoj, ili navedena njegova terapijski prihvatljiva sol, prisutan u terapijski djelotvornoj količini.
11. Pripravak u skladu s patentnim zahtjevima 9 ili 10, naznačen time što dodatno sadrži najmanje jedno dodatno farmaceutsko sredstvo, koje se bira iz skupine koju čine sredstvo protiv pretilosti i antidijabetično sredstvo.
12. Pripravak u skladu s patentnim zahtjevom 11, naznačen time što navedeno sredstvo protiv pretilosti se bira iz skupine koju čine rimonabant, taranabant, surinabant, otenabant, SLV319 (CAS No. 464213-10-3), AVE1625 (CAS No. 358970-97-5)), dirlotapid, mitratapid, implitapid, R56918 (CAS No. 403987), CAS No. 913541-47-6, lorkaserin, cetilistat, PYY3-36, naltrekson, oleoil-estron, obinepitid, pramlintid, tesofenzin, leptin, liraglutid, bromokriptin, orlistat, eksenatid, AOD-9604 (CAS No. 221231-10-3) i sibutramin.
13. Pripravak u skladu s patentnim zahtjevom 11, naznačen time što navedeni antidijabetično sredstvo se bira iz skupine koju čine metformin, acetoheksamid, klorpropamid, Diabinese, glibenklamid, glipizid, gliburid, glimepirid, gliklazid, glipentid, glikidon, glizolamid, tolazamid, tolbutamid, tendamistat, trestatin, akarboza, adipozin, kamigliboza, emiglitat, miglitol, vogliboza, pradimicin-Q, salbostatin, balaglitazon, ciglitazon, darglitazon, englitazon, isaglitazon, pioglitazon, rosiglitazon, troglitazon, eksendin-3, eksendin-4, liraglutid, troduskvemin, rezveratrol, hirtiosalni ekstrakt, sitagliptin, vildagliptin, alogliptin i saksagliptin.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, ili pripravak u skladu s bilo kojim od patentnih zahtjeva 9 do 13, naznačen time što je namijenjen upotrebi u liječenju pretilosti i poremećaja povezanih s pretilošću kod životinja.
15. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, ili pripravak u skladu s bilo kojim od patentnih zahtjeva 9 do 13, naznačen time što je namijenjen upotrebi u liječenju ili odgađanju napredovanja ili početka dijabetesa tip 2 i poremećaja povezanih s dijabetesom kod životinja. Pfizer Inc. Zastupani po:
MEP-2015-9A 2009-11-02 2010-10-21 Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola ME02016B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25714009P 2009-11-02 2009-11-02
US37293810P 2010-08-12 2010-08-12
EP10776433.4A EP2496583B1 (en) 2009-11-02 2010-10-21 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
PCT/IB2010/054775 WO2011051864A1 (en) 2009-11-02 2010-10-21 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Publications (1)

Publication Number Publication Date
ME02016B true ME02016B (me) 2015-05-20

Family

ID=43297093

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-9A ME02016B (me) 2009-11-02 2010-10-21 Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola

Country Status (22)

Country Link
US (5) US8669380B2 (me)
EP (1) EP2496583B1 (me)
JP (1) JP5696156B2 (me)
KR (1) KR101426180B1 (me)
AP (1) AP3099A (me)
AU (1) AU2010310956B2 (me)
CA (1) CA2777857C (me)
CR (1) CR20120289A (me)
DK (1) DK2496583T3 (me)
EA (1) EA021983B1 (me)
EC (1) ECSP12011946A (me)
ES (1) ES2527179T3 (me)
GE (1) GEP20146104B (me)
HR (1) HRP20150107T1 (me)
ME (1) ME02016B (me)
NZ (1) NZ599945A (me)
PL (1) PL2496583T3 (me)
PT (1) PT2496583E (me)
RS (1) RS53827B1 (me)
SI (1) SI2496583T1 (me)
WO (1) WO2011051864A1 (me)
ZA (1) ZA201203486B (me)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102372722A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
WO2012163546A1 (en) * 2011-06-03 2012-12-06 Ratiopharm Gmbh Pharmaceutical composition comprising dapagliflozin and cyclodextrin
US20140228303A1 (en) * 2011-06-13 2014-08-14 Panacea Biotec Ltd Novel sglt inhibitors
WO2013038429A2 (en) 2011-09-13 2013-03-21 Panacea Biotec Ltd. Novel sglt inhibitors
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
ES2740299T3 (es) * 2013-03-14 2020-02-05 Msd Int Gmbh Métodos para preparar inhibidores de SGLT2
WO2014187365A1 (zh) * 2013-05-24 2014-11-27 四川海思科制药有限公司 氧杂双环衍生物、制备方法及其应用
WO2015027963A1 (zh) * 2013-09-02 2015-03-05 四川海思科制药有限公司 芳环类衍生物、其药物组合物及其应用
EP2895490B1 (en) * 2013-09-27 2016-10-19 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivatives and their uses in medicine
RU2696490C2 (ru) 2014-05-19 2019-08-02 Пфайзер Инк. Замещенные-6,8-диоксабицикло[3.2.1.]октан-2,3-диольные соединения в качестве агентов, нацеленных на ASGPR
CN105461762B (zh) * 2014-09-27 2018-12-04 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
HUE055974T2 (hu) 2015-03-03 2022-01-28 Saniona As Tesofensine és metoprolol kombinációs készítmény
CN105646604A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型b及制备方法
CN105646603A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型a及制备方法
CN107382952B (zh) * 2017-07-13 2020-02-28 杭州科巢生物科技有限公司 埃格列净的制备方法及其中间体
CN107857768A (zh) * 2018-01-04 2018-03-30 威海贯标信息科技有限公司 一种埃格列净新晶型
WO2020026273A1 (en) * 2018-07-31 2020-02-06 Msn Laboratories Private Limited, R&D Center Solid forms of ertugliflozin free base and solid dispersions comprising ertugliflozin l-pyroglutamic acid.
CN111269241A (zh) * 2018-12-05 2020-06-12 广西久福生物科技有限公司 一种新型化合物及其制备方法与应用
WO2021137144A1 (en) * 2019-12-31 2021-07-08 Hikal Limited An efficient process for the preparation of ertugliflozin l-pyroglutamic acid and intermediates thereof
CN113214263B (zh) * 2020-02-06 2022-09-30 北京桦冠医药科技有限公司 瑞德西韦关键中间体的一种合成方法
CN117624265A (zh) * 2023-11-27 2024-03-01 江苏海悦康医药科技有限公司 艾托格列净杂质的合成方法

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
JPS5373598A (en) * 1976-12-11 1978-06-30 Teikoku Chem Ind Corp Ltd Saccharide derivatives and process for thir preparation
IE52768B1 (en) 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
JPS5911600B2 (ja) * 1981-04-30 1984-03-16 理化学研究所 ３−アジド−１，６−アンヒドロ−３−デオキシ−２，４−ジ−Ｏ−ベンジル−β−Ｄ−グルコピラノ−ス及びその製造法
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US4590201A (en) 1984-02-02 1986-05-20 Merck & Co., Inc. 5-amino or substituted amino 1,2,3-triazoles
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
NZ214774A (en) 1986-01-08 1989-10-27 Nz Scientific & Ind Res Herbicidal and/or plant growth regulatory compositions based on 1,6-anhydro-beta-hexopyranose derivatives and certain of these derivatives
WO1988003134A1 (en) 1986-10-30 1988-05-05 Terumo Kabushiki Kaisha alpha-HYDROPEROXYISOPROPYLPHENYL COMPOUNDS AND PROCESS FOR THEIR PREPARATION
US5041541A (en) 1988-05-05 1991-08-20 The Procter & Gamble Company Functional sugar substituted with reduced calories
WO1991009537A1 (en) 1989-12-21 1991-07-11 The Procter & Gamble Company Food compositions containing reduced calorie fats and reduced calorie sugars
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
WO1993007167A1 (en) 1991-10-04 1993-04-15 The Procter & Gamble Company Cholesterol lowering compounds and process for making them
CA2079544A1 (en) 1991-10-04 1993-04-05 Adam Weislaw Mazur Cholesterol lowering compounds
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
ATE216704T1 (de) 1996-12-26 2002-05-15 Tanabe Seiyaku Co Propiophenonderivate und verfahren zu ihrer herstellung
WO1998041648A2 (en) 1997-03-20 1998-09-24 Variagenics, Inc. Target genes for allele-specific drugs
US6486299B1 (en) 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
US6069238A (en) 1998-09-30 2000-05-30 Eli Lilly And Company Spirocyclic C-glycosides
EP1213296B1 (en) 1999-08-31 2004-04-14 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
WO2001042469A1 (en) 1999-12-10 2001-06-14 Lexicon Genetics Incorporated Novel human transporter protein and polynucleotides encoding the same
US6627611B2 (en) 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
WO2001057214A2 (en) 2000-02-03 2001-08-09 Lexicon Genetics Incorporated Human transporter proteins and polynucleotides encoding the same
DE10006887A1 (de) 2000-02-16 2001-09-06 Hermann Koepsell Verbindungen, die die Aktivität oder die Konzentration des Regulatorproteins RS1 verändern
ES2254376T3 (es) 2000-03-17 2006-06-16 Kissei Pharmaceutical Co., Ltd. Derivados glucopiranosiloxibencilbenceno, preparaciones medicinales que los contienen e intermediarios para la preparacion de los indicados derivados.
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
JP3798375B2 (ja) 2000-09-29 2006-07-19 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体およびそれを含有する医薬組成物
WO2002036602A1 (en) 2000-11-02 2002-05-10 Ajinomoto Co., Inc. Novel pyrazole derivatives and diabetes remedies containing the same
WO2002044192A1 (en) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
US20020081678A1 (en) 2000-12-11 2002-06-27 Gennady Merkulov Isolated nucleic acid molecules encoding human transporter proteins, and uses thereof
SK287786B6 (sk) 2000-12-28 2011-09-05 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie
US7247705B2 (en) 2000-12-28 2007-07-24 Takeda Pharmaceutical Company Limited Proteins having glucose transporter activity
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
EP1364957B1 (en) 2001-02-26 2008-12-31 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
WO2002068440A1 (en) 2001-02-27 2002-09-06 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
CA2439152C (en) 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US20050089955A1 (en) 2001-03-27 2005-04-28 Fangcheng Gong Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
US20030045553A1 (en) 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
US20030054453A1 (en) 2001-04-10 2003-03-20 Millennium Pharmaceuticals, Inc. 68723, sodium/glucose cotransporter family members and uses therefor
DK1385856T3 (da) 2001-04-11 2006-05-15 Bristol Myers Squibb Co Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
EP1389621A4 (en) 2001-04-27 2005-05-11 Ajinomoto Kk N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
CA2448741C (en) 2001-05-30 2010-06-22 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
US7271153B2 (en) 2001-06-20 2007-09-18 Kissei Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor
JP4115105B2 (ja) 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
WO2003011880A1 (fr) 2001-07-31 2003-02-13 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
US20030087843A1 (en) 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
WO2003055914A2 (en) 2001-12-21 2003-07-10 7Tm Pharma A/S Modified receptors for the discovery of therapeutic ligands
AU2002357449A1 (en) 2001-12-21 2003-07-15 7Tm Pharma A/S Use of a signal transduction complex in drug discovery processes
AU2002367140A1 (en) 2001-12-27 2003-07-15 Takeda Chemical Industries, Ltd. Human sglt homolog promoter and use thereof
DE10212557A1 (de) 2002-03-14 2003-09-25 Univ Schiller Jena Verfahren zur Charakterisierung hochparallelisierter Liquidhandlingtechnik mittels Mikroplatten sowie Testkit zur Durchführung des Verfahrens
PL210710B1 (pl) 2002-03-22 2012-02-29 Kissei Pharmaceutical Krystaliczne postaci 2-(4-metoksybenzylo) fenylo-6-O-etoksykarbonylo-ß-D-glukopiranozydu, ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna
US20070059356A1 (en) 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DE10225844A1 (de) 2002-06-04 2003-12-18 Lang Florian sgk und nedd als diagnostische und therapeutische targets
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
BRPI0313290B1 (pt) 2002-08-08 2016-12-06 Kissei Pharmaceutical derivados de pirazol, promedicamento, composição farmacêutica, agentes terapêuticos e uso medicinal
MXPA05000725A (es) 2002-08-09 2005-04-08 Taisho Pharma Co Ltd Procedimiento para la produccion selectiva de aril-5-tio-??-d-aldohexopiranosidos.
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
WO2004019958A1 (ja) 2002-08-27 2004-03-11 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
WO2004039405A1 (ja) 2002-10-29 2004-05-13 Takeda Pharmaceutical Company Limited Ｓｇｌｔホモログ用途
JP4651934B2 (ja) 2002-12-04 2011-03-16 キッセイ薬品工業株式会社 ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
EP1568380A4 (en) 2002-12-04 2009-10-21 Kissei Pharmaceutical PREVENTION OR TREATMENT OF DISEASES DUE TO HYPERGLYCEMIA
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
AU2003289440A1 (en) 2002-12-25 2004-07-22 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
PL378324A1 (pl) 2003-01-03 2006-03-20 Bristol-Myers Squibb Company Sposób wytwarzania C-aryloglukozydowych inhibitorów SGLT2
KR20050111752A (ko) 2003-03-07 2005-11-28 쓰레솔드 파마슈티컬스, 인코포레이티드 항신생물제에 의한 치료에 대한 종양의 감수성을 결정하는방법
ATE510834T1 (de) 2003-03-14 2011-06-15 Astellas Pharma Inc C-glykosid-derivate zur behandlung von diabetes
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
WO2004089966A1 (ja) 2003-04-01 2004-10-21 Taisho Pharmaceutical Co., Ltd. 選択的なヘテロアリール ５－チオ－β－Ｄ－アルドヘキソピラノシドの製造法
CN1761676A (zh) 2003-04-01 2006-04-19 大正制药株式会社 杂芳基5－硫代－β－D－吡喃葡糖苷衍生物及含有该衍生物的糖尿病治疗药
WO2004093544A1 (ja) 2003-04-24 2004-11-04 Ishihara Sangyo Kaisha, Ltd. 置換ベンゼン誘導体又はその塩、それらの製造方法、並びにそれらを有効成分として含有する殺菌剤
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
JPWO2004106352A1 (ja) 2003-05-29 2006-07-20 大正製薬株式会社 アルドヘキソピラノース中間体の製造法
JP2004359630A (ja) 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd ジフルオロジフェニルメタン誘導体及びその塩
WO2004113359A1 (ja) 2003-06-20 2004-12-29 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体
CN104109155A (zh) 2003-08-01 2014-10-22 田边三菱制药株式会社 新颖化合物
EP1679965A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED ANELLIERED HETEROCYCLIC C-GLYCOSIDES
WO2005012243A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
AU2004261663A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
CA2549017A1 (en) 2003-08-01 2005-02-10 Mona Patel Substituted indazole-o-glucosides
CA2539032A1 (en) 2003-08-26 2005-03-10 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US7371732B2 (en) 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
JP2005247834A (ja) 2004-02-04 2005-09-15 Taisho Pharmaceut Co Ltd ナトリウム依存性グルコース供輸送体２の活性阻害剤
AU2005219779B2 (en) 2004-03-04 2011-04-14 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
AU2005219776B2 (en) 2004-03-04 2010-07-08 Kissei Pharmaceutical Co., Ltd. Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
CA2557320C (en) 2004-03-04 2013-02-05 Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivatives for prevention or treatment of hyperglycemia
EA011158B1 (ru) 2004-03-16 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
WO2005095372A1 (ja) 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途
WO2005095373A1 (ja) 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. ナフタレン誘導体、それを含有する医薬組成物およびその医薬用途
US20070185197A1 (en) 2004-03-31 2007-08-09 Hideki Fujikura Phenol derivative, medicinal composition containing the same, and medicinal use thereof
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
JPWO2006006496A1 (ja) 2004-07-08 2008-04-24 アステラス製薬株式会社 アズレン誘導体の製造方法及びその合成中間体
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
MX2007000811A (es) 2004-07-21 2007-04-02 Kissei Pharmaceutical Inhibidor de avance de enfermedad atribuida a acumulacion anormal de grasa en el higado.
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
WO2006010557A1 (de) 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
JP2006117651A (ja) 2004-09-27 2006-05-11 Taisho Pharmaceut Co Ltd Ｓｇｌｔ２の活性阻害剤
CA2581922A1 (en) 2004-09-29 2006-04-06 Kissei Pharmaceutical Co., Ltd. 1-(.beta.-d-glycopyranosyl)-3-substituted nitrogenous heterocyclic compound, medicinal composition containing the same, and medicinal use thereof
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006054629A1 (ja) 2004-11-18 2006-05-26 Kissei Pharmaceutical Co., Ltd. １－置換－３－（β－Ｄ－グリコピラノシル）含窒素ヘテロ環化合物、及びそれを含有する医薬
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
JP2008524162A (ja) 2004-12-16 2008-07-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) * 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
US7749972B2 (en) 2005-02-15 2010-07-06 Kissei Pharmaceutical Co., Ltd. 1-substituted-7-(β-D-glycopyranosyloxy)(aza)indole compound and pharmaceutical containing the same
JP5264183B2 (ja) 2005-02-23 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換（（ヘテロ）アリールエチニル−ベンジル）−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体２（ｓｇｌｔ２）インヒビターとしてのそれらの使用
WO2006090577A1 (ja) 2005-02-24 2006-08-31 Mayekawa Mfg. Co., Ltd. ロース・ばら部の肋骨脱骨方法及び装置
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
WO2006108584A2 (en) 2005-04-15 2006-10-19 Cenix Bioscience Gmbh Human marker genes and agents for cardiovascular disorders and artherosclerosis
WO2006108842A1 (en) 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
JPWO2006115137A1 (ja) 2005-04-22 2008-12-18 キッセイ薬品工業株式会社 ２−アミノベンズイミダゾール誘導体及びその医薬用途
WO2006119038A1 (en) 2005-04-29 2006-11-09 Naturegen, Inc. Compositions and methods for controlling glucose uptake
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AU2006253805A1 (en) 2005-05-27 2006-12-07 Actelion Pharmaceuticals Ltd. Novel piperidine carboxylic acid amide derivatives
WO2007000445A1 (en) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200726755A (en) 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
EP1910390B1 (en) 2005-07-27 2010-05-19 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted ((hetero)cycloalyklethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
UY29694A1 (es) 2005-07-28 2007-02-28 Boehringer Ingelheim Int Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
WO2007019526A2 (en) 2005-08-05 2007-02-15 Naturegen, Inc. Compositions and methods for controlling glucose and lipid uptake from foods
JP5175191B2 (ja) 2005-08-30 2013-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
JPWO2007029668A1 (ja) 2005-09-08 2009-03-19 国立大学法人金沢大学 ソフトイオン化法のための誘導体化試薬
BRPI0615882A2 (pt) 2005-09-08 2011-05-31 Boehringer Ingelheim Int formas cristalinas de 1-cloro-4-(beta-d-glicopiranos-1-il)-2-(4-etinil-benzil)- benzeno, métodos para sua preparação e o uso para preparar medicamentos do mesmo
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
US20070099237A1 (en) 2005-10-31 2007-05-03 The Regents Of The University Of Michigan Reaction co-crystallization of molecular complexes or co-crystals
AR059489A1 (es) 2006-02-15 2008-04-09 Boehringer Ingelheim Vetmed Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
JP2009167104A (ja) 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd フェニル５−チオグリコシド化合物
JP2009167103A (ja) 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd ピラゾリル５−チオグリコシド化合物
EP1854806A1 (en) 2006-05-02 2007-11-14 MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Thioglycosides as pharmaceutically active agents
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
RU2437876C2 (ru) 2006-05-19 2011-12-27 Тайсо Фармасьютикал Ко., Лтд. Соединение с-фенилглицитола для лечения диабета
WO2007140191A2 (en) * 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
KR20090023570A (ko) 2006-06-29 2009-03-05 다이쇼 세이야꾸 가부시끼가이샤 Ｃ-페닐 1-티오글루시톨 화합물
TWI403516B (zh) * 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI418556B (zh) 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
JP2008050353A (ja) 2006-07-27 2008-03-06 Mitsubishi Tanabe Pharma Corp 医薬組成物
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
CA2656847A1 (en) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
CA2664095A1 (en) 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
BRPI0719523A2 (pt) 2006-10-13 2015-06-16 Chugai Pharmaceutical Co Ltd Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes
DE102006048728A1 (de) 2006-10-16 2008-04-17 Merck Patent Gmbh 3-Amino-imidazo{1,2-a]pyridinderivate
US8283326B2 (en) 2006-10-27 2012-10-09 Boehringer Ingelheim International Gmbh Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
AR063569A1 (es) 2006-11-06 2009-02-04 Boehringer Ingelheim Int Derivados de benzil- benzonitrilo sustituidos con glucopiranosilo medicamentos que contienen a compuestos de este tipo su uso u procedimiento para su fabricacion
CL2007003227A1 (es) 2006-11-09 2008-07-04 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo en combinacion con uno o mas agentes terapeuticos; y uso para el tratamiento de diabetes mellitus, obesidad e hiperglucemia entre otras.
TW200845956A (en) 2006-12-18 2008-12-01 Smithkline Beecham Corp Calcilytic compounds
US7846945B2 (en) 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
WO2008115574A1 (en) 2007-03-21 2008-09-25 Reliant Pharmaceuticals, Inc. Cb1 antagonist and a dyslipidemic agent and/or metabolic regulator, and methods of making and using same
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
UA107175C2 (uk) 2007-07-26 2014-12-10 Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
CL2008002425A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
AU2008288770B2 (en) 2007-08-23 2014-06-12 Theracosbio, Llc Benzylbenzene derivatives and methods of use
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
ES2380408T3 (es) * 2008-08-28 2012-05-11 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol

Also Published As

Publication number Publication date
US9308204B2 (en) 2016-04-12
CA2777857C (en) 2014-12-02
ES2527179T3 (es) 2015-01-21
ZA201203486B (en) 2013-07-31
KR101426180B1 (ko) 2014-07-31
EP2496583A1 (en) 2012-09-12
KR20120093321A (ko) 2012-08-22
EA201290267A1 (ru) 2012-12-28
ECSP12011946A (es) 2012-07-31
US20120184486A1 (en) 2012-07-19
US8669380B2 (en) 2014-03-11
CA2777857A1 (en) 2011-05-05
EP2496583B1 (en) 2014-12-10
AP2012006281A0 (en) 2012-06-30
GEP20146104B (en) 2014-05-27
NZ599945A (en) 2014-05-30
US20150065512A1 (en) 2015-03-05
US20130225487A1 (en) 2013-08-29
AP3099A (en) 2015-01-31
EA021983B1 (ru) 2015-10-30
HRP20150107T1 (xx) 2015-03-13
US9439902B2 (en) 2016-09-13
AU2010310956A1 (en) 2012-06-07
WO2011051864A1 (en) 2011-05-05
CR20120289A (es) 2012-09-26
US20150065513A1 (en) 2015-03-05
PT2496583E (pt) 2015-01-14
AU2010310956B2 (en) 2014-05-08
RS53827B1 (sr) 2015-06-30
SI2496583T1 (sl) 2015-02-27
JP5696156B2 (ja) 2015-04-08
PL2496583T3 (pl) 2015-04-30
US20150065565A1 (en) 2015-03-05
US9439901B2 (en) 2016-09-13
DK2496583T3 (en) 2015-02-02
JP2013509393A (ja) 2013-03-14

Similar Documents

Publication Publication Date Title
JP2013509393A5 (me)
US6500838B2 (en) Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
JP2011521940A5 (me)
NZ595024A (en) Benzofuranyl derivatives used as glucokinase inhibitors
CN116710446B (zh) Glp-1r激动剂的晶型及其用途
US10813890B2 (en) Pharmaceutical combination
JP2017519025A5 (me)
US11357777B2 (en) Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)
RU2006133898A (ru) Производные бензимидазола и его применение
MXPA05010171A (es) Agonistas de receptor muscarinico m1 para manejo del dolor.
RU2006133118A (ru) Средство для чрескожного введения никотина
KR20040044953A (ko) 요실금 치료를 위한, 무스카린 길항제와 선택된오피오이드와의 배합물
JP2015518007A (ja) スケドスポリウム属感染症の治療方法
WO2016144727A1 (en) Peripheral-anticholinergic muscarinic agonist combination
AU2003277077B2 (en) Use of nefopam for the treatment of nausea or emesis
JP2007500676A (ja) 抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤
CA2685126A1 (en) Therapeutic or prophylactic agent for dyskinesia
AU700520B2 (en) NK-1 receptor antagonists for the treatment of cancer
Holmquist et al. Effects of the α1-adrenoceptor antagonist R-(−)-YM12617 on isolated human penile erecetile tissue and vas deferens
AU2002327635B2 (en) Enhancement of learning and memory and treatment of amnesia
NZ280627A (en) use of a NK-1 receptor antagonist in the treatment of central nervous system, brain and other neuronal disorders
WO2007061868A2 (en) Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors
JP2022554230A5 (me)
AU2002327635A1 (en) Enhancement of learning and memory and treatment of amnesia
US20060167114A1 (en) Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors